Clinical Trial: Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797036) titled 'Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes' on Aug. 27.

Brief Summary: This is an effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design to evaluate the effectiveness and potential real-world integration of immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). A total of 226 postpartum individuals with recent GDM will be randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, will be assessed at 6 mon...